Aqua Metals, Inc. (AQMS) Q4 2024 Earnings Conference Call March 31, 2025 04:30 PM ET Company Participants Conference Moderator - ModeratorJudd Merrill - Chief Financial OfficerTeleconference Operator - OperatorSteve Cotton - President and Chief Executive OfficerBob Myers - Investor Relations Conference Call Participants Mickey Legg - Analyst, Benchmark Company Teleconference Operator An answer session will follow the presentation. You may submit questions via the webcast at any time by using the ask a quest ...

BioCardia, Inc. (BCDA) Q4 2024 Earnings Conference Call March 31, 2025 04:30 PM ET Company Participants Conference Operator - ModeratorMiranda Vito - BioCardia and Vesta Relations RepresentativeDr. Peter Altman - President and CEO, BioCardiaDavid McClung - Chief Financial Officer, BioCardiaKumar Raja - Investor, Brookline Capital Markets Conference Call Participants Joe Pangenese - Analyst, HC WainwrightJames F. Malloy - Analyst, Alliance Global Partners Conference Operator Ladies and gentlemen, thank you f ...

Venu Holding Corporation (VENU) Q4 2024 Earnings Conference Call March 31, 2025 04:30 PM ET Company Participants Conference Call Operator - Operator/ModeratorHeather Atkinson - Chief Financial Officer, Venue Holding CorporationJ.W. Roth - Founder, Chairman, and Chief Executive Officer, Venue Holding CorporationTerry Liebler - Chief Marketing Officer, Venue Holding CorporationRay Oliver - Investor, Bear Creek CapitalJohn Lutz - Representative, iHIT Industries LLCWill Hodson - President, Venue Holding Corpora ...

Financial Data and Key Metrics Changes - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $27.6 million, down from $48.5 million as of December 31, 2023, indicating a significant decrease in liquidity [40] - The net loss for Q4 2024 was $15.7 million, compared to a net loss of $14.1 million in Q4 2023. For the full year 2024, the net loss was $56.6 million, down from $67.9 million in 2023, reflecting a reduction in overall losses [45] Business Line Data and Key Metrics Changes - Contract revenue for Q4 2024 was approximately $1 million, with no contract revenue reported for the same period in 2023, indicating a new revenue stream [41] - Research and development expenses for Q4 2024 were $6.8 million, down from $7.6 million in Q4 2023. For the full year, R&D expenses decreased to $26.7 million from $39.6 million in 2023, attributed to cost containment measures [42] Market Data and Key Metrics Changes - The obesity market is projected to reach $100 billion by 2030, highlighting significant growth potential for oral alternatives in treatment [19] Company Strategy and Development Direction - The company aims to leverage its Ronnie Pill technology to develop next-generation obesity therapies, focusing on RT-114 and semaglutide programs [10][20] - A strategic partnership was established with Progen Co Limited for the co-development and commercialization of RT-114, combining their GLP-1, GLP-2 dual agonist with the Ronnie Pill [20][21] - The company is open to additional partnerships to advance oral biologics across various indications, including immunology and endocrinology [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the advancements made in the pipeline, particularly in the obesity space, and plans to bring RT-114 into clinical trials by mid-2025 [48] - The management highlighted the potential of the Ronnie Pill platform to redefine the treatment paradigm for injectable large molecule therapeutics [48] Other Important Information - The company has a robust patent portfolio with over 450 granted patents and pending applications, supporting its innovative delivery technology [15] Q&A Session Summary Question: Development of oral semaglutide and capital constraints - Management confirmed that the primary focus is on RT-114 due to capital constraints, and while RT-116 is a discovery program, it is not currently planned for clinical study [55][56] Question: Variability in weight loss with RT-114 - Management explained that the transenteric route has shown to be more efficient than subcutaneous delivery, leading to less variability in weight loss outcomes [70] Question: Tolerability and dosing flexibility for RT-114 - Management emphasized that tolerability is key and that the oral formulation allows for flexible dosing, which can be adjusted based on patient response [78][80] Question: Comparison of PG-102 with other GLP-1, GLP-2 therapies - Management noted that PG-102 has shown sustained weight loss over time compared to other therapies, and the FC fusion protein nature of PG-102 allows for rapid titration without the need for extensive dose adjustments [100] Question: Future studies for RT-114 - Management confirmed that no additional animal studies are planned before entering clinical trials, expressing confidence based on previous studies [104] Question: Regulatory pathway for PG-102 - Management indicated that Progen is moving forward with Phase 2A studies for PG-102 and plans to file an IND in the near future, which could benefit the RT-114 program [112]

Financial Data and Key Metrics Changes - Sales net of returns and allowances for the full year 2024 were $6.6 million, a decrease from $13.1 million in 2023, primarily due to lower W4CC truck sales, offset by an increase in W56 truck sales and service revenue [43] - Cost of sales for 2024 was $28.2 million, down $9.5 million from $38.4 million in 2023, driven by lower W4CC vehicle sales and cost-saving initiatives [44] - SG&A expenses decreased to $42.5 million in 2024 from $55.6 million in 2023, primarily due to reduced employee compensation and consulting expenses [45] - R&D expenses for 2024 were $9.1 million, a decrease of $15.3 million compared to $24.5 million in 2023, mainly due to lower headcount and reduced prototype expenses [46] - The net loss for 2024 was $101.8 million, compared to a net loss of $123.9 million in 2023 [48] Business Line Data and Key Metrics Changes - The decrease in sales was primarily attributed to lower W4CC truck sales, while W56 truck sales increased, contributing positively to service revenue [43] - The company launched the new W56 208-inch wheelbase truck, receiving positive customer feedback and a purchase order for 13 units [11] Market Data and Key Metrics Changes - The commercial EV market is experiencing uncertainty due to regulatory pauses and delays in fleet electrification plans, impacting investment decisions by several fleets [8][9] - Despite challenges, some states continue to advance their electrification plans, and Workhorse is positioned to capitalize on these opportunities [9] Company Strategy and Development Direction - The company aims to extend its financial runway while advancing its product roadmap and ramping up production [53] - Workhorse is focused on securing breakthrough high-volume orders with national fleets and smaller orders in states with effective incentive programs [57] - The company emphasizes its commitment to delivering reliable, durable, and capable commercial vehicles that meet the needs of last-mile delivery fleets [38] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that EV adoption in the commercial space is slower than expected due to external factors such as regulatory delays and inadequate charging infrastructure [54] - The company remains optimistic about the fundamentals of transitioning to EVs in the last-mile delivery segment, highlighting the operational benefits of their vehicles [55] Other Important Information - The company executed a one-for-12.5 reverse stock split to increase the market price of its common stock and maintain compliance with NASDAQ listing requirements [48] - Workhorse has established in-house manufacturing capabilities, making it the only North American-based OEM capable of producing complete step vans [20] Q&A Session Summary - No specific questions were recorded during the Q&A session, and the call concluded with management expressing gratitude for the support and commitment to securing necessary orders for future growth [61][62]

Financial Data and Key Metrics Changes - The company reported a total revenue of $54 million for 2024, an increase of $5.2 million or 11% compared to $48.8 million in 2023 [25] - Adjusted EBITDA in Q4 2024 was a profit of $0.5 million, a significant improvement of almost $5 million from a loss of $4.3 million in Q4 2023 [13][35] - The net loss for 2024 was $11.8 million compared to $10.2 million in 2023, while the net loss in Q4 2024 was $1.2 million compared to $3.5 million in Q4 2023 [35][36] Business Line Data and Key Metrics Changes - Sales in Germany increased by over 183% in 2024, reaching $15.5 million, with Germany accounting for 40% of total revenue in the second half of 2024 compared to 11% in all of 2023 [15][25] - In Israel, revenue decreased by $4.8 million net, primarily due to the cancellation of the Oranim deal, which resulted in a revenue decrease of approximately $8.5 million compared to 2023 [25][27] - The company launched or relaunched 27 strains across six brands in Israel in 2024, maintaining top-line sales despite the challenges [17] Market Data and Key Metrics Changes - The German market has shown extraordinary growth since the partial legalization in April 2024, with a significant increase in sales velocity [8][15] - The company added three new suppliers and launched 16 new strains in 2024, indicating a strong operational focus on the German market [12][14] Company Strategy and Development Direction - The company focused on full integration and active cost management to drive efficiencies, reducing overall operating expenses by $4 million or 17% in 2024 [11] - The strategic shift towards the German market has proven effective, with plans to continue building a strong supply chain to support growth in 2025 [10][20] - The company aims to maintain efficiency while investing in growth, particularly in Germany, while not expecting significant growth in the Israeli market [57] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the operational improvements made in 2024, setting a solid foundation for growth in 2025, with Q1 expected to be the best quarter in sales to date in Germany [19][40] - The competitive landscape in Germany is dynamic, with expectations of price compression, but management believes margins will not decline significantly [50][52] Other Important Information - The company cleared out slow-moving non-premium stock, impacting cost of sales and gross margin, but does not anticipate similar write-offs in 2025 [18] - Total operating expenses for 2024 were $18.7 million, down from $22.6 million in 2023, reflecting improved operational efficiency [34] Q&A Session Summary Question: Dynamics affecting growth in Germany in Q4 - Management acknowledged delays in Q4 but indicated that Q1 looks promising, attributing the slowdown to supply chain building processes [46] Question: Changes in competitive dynamics in Germany - Management noted that the German market is competitive, with ongoing price compression, but does not foresee significant changes in leading competitors [48][50] Question: Margin profile expectations amid price compression - Management expects margins to remain stable or improve, despite the challenges faced in 2024 due to inventory issues [52][54] Question: Stability of the Israeli market - Management does not foresee significant growth in the Israeli market, focusing resources primarily on the German market [57]

Financial Data and Key Metrics Changes - Total revenues for the year ended December 31, 2024, were $28.9 million, an increase of $24.1 million, or 502.1%, compared to $4.8 million for the year ended December 31, 2023 [30] - Net loss for the year ended December 31, 2024, was $9.2 million compared to a net loss of $60.6 million for the year ended December 31, 2023 [34] - Cash, cash equivalents, and short-term bank deposits as of December 31, 2024, were $19.6 million, with approximately $29 million on a pro forma basis after financing completed in early January 2025 [34] Business Line Data and Key Metrics Changes - APHEXDA achieved a 10% market share of total CXCR4 inhibitor usage in the U.S. within less than 11 months of being on the market [26] - Generated more than $6 million of net APHEXDA product revenue in the U.S. through the closing of the Ayrmid transaction on November 21 [27] Company Strategy and Development Direction - The company has shifted its strategy to focus on evaluating early clinical stage and late pre-clinical stage therapeutic assets in oncology and rare diseases [6][7] - The licensing agreement with Ayrmid Pharma Ltd. allows the company to return to its roots in complex drug development while leveraging expertise in drug development [6][9] - The company aims to help as many patients as possible while creating enduring value for shareholders [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about evaluating several promising candidates and the potential for definitive announcements within the year [8] - The company has reduced its ongoing operating cash burn by approximately 70%, from over $40 million annually to approximately $12 million annually [18] - The company believes it is well-positioned to advance motixafortide in solid tumor indications while evaluating additional assets in oncology and rare diseases [19] Other Important Information - The Ayrmid agreement generated $10 million in upfront payments and potential milestones of $87 million, along with double-digit sales royalties ranging from 18% to 23% [16] - The company has shut down its U.S. operations and implemented a headcount reduction in Israel, transitioning a substantial portion of its commercial team to Ayrmid [17] Q&A Session Summary Question: Any more color on meaningful progress in evaluating assets? - Management indicated that they are having meaningful discussions regarding early-stage clinical assets in oncology and rare diseases but could not provide a timeline for announcements [38] Question: How are internal programs looking, especially with WashU and sickle cell? - Management noted that a significant win would be mobilizing enough cells in one cycle for gene therapy, reducing the number of apheresis sessions required [43][44] Question: Commentary on increased traction of APHEXDA for multiple myeloma? - Management expressed confidence in Ayrmid's team and their marketing efforts, stating that the transition has gone smoothly [49] Question: How many assets have been looked at in the acquisition process? - Management stated that they have looked at thousands of molecules over the company's history, focusing on early clinical stage assets in oncology and rare diseases [56][58] Question: Allocation of expenses during the acquisition process? - Management confirmed that expenses would initially be higher during the search process but would shift towards R&D once assets are acquired [59] Question: Internal versus external efforts in the acquisition process? - Management indicated that the majority of the work is done in-house, with external consultants used as needed for specific expertise [64]

FTC Solar (FTCI) Q4 2024 Earnings Call March 31, 2025 02:36 PM ET Company Participants Bill Michalek - Vice President of Investor Relations & Corporate CommunicationsYann Brandt - President & CEOCathy Behnen - Chief Financial Officer Conference Call Participants Philip Shen - Managing Director, Senior Research AnalystJeffrey Osborne - Analyst Operator Good day and thank you for standing by. Welcome to the FTC Solar Fourth Quarter twenty twenty four Earnings Conference Call. At this time, all participants ar ...

Financial Data and Key Metrics Changes - In 2024, the company mined 170.6% Bitcoin, generating approximately $11 million in revenue and $3.9 million in core EBITDA, indicating strong growth compared to previous periods [11][10] - For Q4 2024, total revenue was approximately $2 million, down from $4.1 million in Q4 2023, primarily due to the April 2024 Bitcoin halving event [20][21] - The net income attributable to LM shareholders for Q4 2024 was $2 million, a significant improvement from a net loss of $1.6 million a year ago [22] - Core EBITDA for Q4 2024 increased to $3.3 million, nearly 10 times what was generated a year ago [23] Business Line Data and Key Metrics Changes - The company transitioned to a vertically integrated model, managing its own mining infrastructure, which has improved margins and reduced energy costs [7][9] - The acquisition of a 15 megawatt mining facility in Oklahoma marked a significant operational achievement [16] Market Data and Key Metrics Changes - The average Bitcoin price during Q4 2024 was approximately $83,000, while the average for the full year was about $61,000 [20] - As of February 25, 2025, the company expanded its total energized hash rate to 560 petahash per second and held 165.8% Bitcoin on its balance sheet [11] Company Strategy and Development Direction - The company plans to invest in next-generation mining hardware, energy efficiency initiatives, and strategic site acquisitions to support growth [14][26] - The focus remains on acquiring smaller power assets in the 5 to 20 megawatt range, which are often overlooked by larger operators [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating industry volatility and emphasized the importance of vertical integration and disciplined cost management for future success [25][13] - The company believes its current market cap presents a compelling value relative to its Bitcoin holdings, which are valued significantly higher than the market cap [12] Other Important Information - The company retained a portion of its mined Bitcoin to capture potential upside for shareholders and deepen alignment with the broader Bitcoin industry [10] - The combined cash and Bitcoin holdings increased by 200% in fiscal year 2024, with cash growing 40% to $3.4 million and Bitcoin holdings surging over 300% to $14 million [23] Q&A Session Summary Question: Current operating stats and new machines - The 256 new machines have not yet arrived and will be added once installed [31] Question: Open sockets and deployment of new machines - There is space to add about two more megawatts, and the new machines will replace less efficient ones [33][35] Question: Timeline for new containers - Groundwork for the new containers is expected to take about three weeks, with installation within 90 days [38] Question: Opportunities in Texas - The company has looked at several sites in Texas but currently has no outstanding letters of intent [40] Question: Deployment of Luxor OS2 - Luxor OS2 has been deployed on all machines at the Calumet mining site but not on those at core [42] Question: Details on the secured loan - The $5 million secured loan is primarily for the new mining site in Oklahoma, structured to avoid liquidating Bitcoin [45]

Financial Data and Key Metrics Changes - Revenue for Q3 2024 was $10.1 million, a decrease of 11.3% compared to the prior quarter and a decrease of 66.8% year-over-year due to lower product volumes [34] - GAAP gross loss was $4.3 million, or 42.5% of revenue, compared to a gross loss of $2.3 million, or 20.5% of revenue in the prior quarter [35] - GAAP net loss was $15.4 million, or $0.12 per diluted share, compared to a loss of $12.2 million, or $0.10 per diluted share in the prior quarter [37] - Adjusted EBITDA loss was $12.2 million, which was better than the midpoint of guidance, compared to losses of $10.5 million in the prior quarter [38] - The company ended the quarter with $8.3 million in cash on the balance sheet [39] Business Line Data and Key Metrics Changes - Over 70% of current purchase orders are in the 1P category, indicating a significant shift from previous quarters where 1P revenues were only 16% and 30% in Q2 and Q3 respectively [13] - The company has transitioned from a 2P only company to one that offers both 1P and 2P solutions, significantly increasing the total addressable market [15] Market Data and Key Metrics Changes - The company is seeing strong growth in the Northeast and Southwest U.S. markets, with opportunities expanding in the Southeast due to high wind product offerings [46] - The company has signed a multi-year supply agreement with Strata Clean Energy for at least 500 megawatts of 2P trackers, which could expand to over 1 gigawatt [28] Company Strategy and Development Direction - The company is focused on expanding its 1P product offerings, which now include high wind solutions and compatibility for various module types, to capture a larger market share [14] - The management believes that the company is poised to achieve quarterly profitability in 2025, driven by strong margins and a robust product cost structure [25] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the solar market's resilience, noting that solar has experienced growth regardless of political changes [48] - The company expects to see continued improvement in revenue, margin, and adjusted EBITDA in Q4, with a target of achieving adjusted EBITDA breakeven on a quarterly basis in 2025 [41] Other Important Information - The company entered into a binding term sheet for a $15 million promissory note, which is expected to close by the end of November [21] - The company received an additional $4.7 million in cash from an earn-out on a prior investment, improving its liquidity position [39] Q&A Session Summary Question: What proportion of the backlog is coming from 1P revenues? - Management indicated that about 70% of signed purchase orders are in the 1P category, with expectations for revenue growth from this segment [43] Question: How is the geographic distribution of projects? - The company has a diverse geographic focus, with strong growth in the Northeast, Southwest, and Southeast markets [46] Question: What is the breakeven revenue range? - Management confirmed that the breakeven revenue range remains at $50 million to $60 million, consistent with previous discussions [51] Question: What is the outlook for 2025 revenue guidance? - Management expects about 60% of the signed backlog to start recognizing revenue in 2025, indicating strong growth potential [53] Question: Will there be opportunities for 1P in the Strata supply agreement? - Currently, the agreement is for 2P delivery, but there are expectations for future opportunities to cross-sell between 1P and 2P products [54]